Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis

Anjali Ganda, MD, MS*; Martin Magnusson, MD, PhD*; Laurent Yvan-Charvet, PhD; Bo Hedblad, MD, PhD; Gunnar Engström, MD, PhD; Ding Ai, PhD; Thomas J. Wang, MD; Robert E. Gerszten, MD; Olle Melander, MD, PhD†; Alan R. Tall, MBBS‡

Background—The number of circulating blood monocytes impacts atherosclerotic lesion size, and in mouse models, elevated levels of high-density lipoprotein cholesterol suppress blood monocyte counts and atherosclerosis. We hypothesized that individuals with mild renal dysfunction at increased cardiovascular risk would have reduced high-density lipoprotein levels, high blood monocyte counts, and accelerated atherosclerosis.

Methods and Results—To test whether mild renal dysfunction is associated with an increase in a leukocyte subpopulation rich in monocytes that has a known association with future coronary events, we divided individuals from the Malmö Diet and Cancer study (MDC) into baseline cystatin C quintiles (n=4757). Lower levels of renal function were accompanied by higher monocyte counts, and monocytes were independently associated with carotid bulb intima-media thickness cross-sectionally (P=0.02). Cystatin C levels were positively and plasma high-density lipoprotein cholesterol levels negatively associated with monocyte counts at baseline, after adjustment for traditional risk factors. Several amino acid metabolites tied to low levels of high-density lipoprotein cholesterol and insulin resistance measured in a subset of individuals (n=752) by use of liquid chromatography–mass spectrometry were independently associated with a 22% to 34% increased risk of being in the top quartile of monocytes (P<0.05).

Conclusions—A low high-density lipoprotein cholesterol, insulin resistance phenotype occurs in subjects with mild renal dysfunction and is associated with elevated monocytes and atherosclerosis. High blood monocyte counts may represent a previously unrecognized mechanism underlying the strong relationship between cystatin C and cardiovascular risk.

(Circulation. 2013;127:988–996.)

Key Words: atherosclerosis ■ immunology ■ kidney ■ metabolomics ■ risk factors

Patients with chronic kidney disease (CKD) have a markedly increased risk of atherosclerotic cardiovascular disease.1 The risk of cardiovascular events increases as the estimated glomerular filtration rate declines.2 Although CKD may be associated with several well-known atherosclerosis risk factors, such as diabetes, hypertension, and elevated blood cholesterol, the atherosclerosis in patients with CKD is not fully explained by traditional risk factors.3 The recent SHARP trial (Study of Heart and Renal Protection)4 demonstrated a 17% relative risk reduction in first major atherosclerotic event in 9270 CKD patients receiving simvastatin plus ezetimibe versus placebo; however, event rates remained high in treated patients, and similar to 2 previous trials in hemodialysis patients, there was no significant reduction in mortality or nonfatal myocardial infarction from low-density lipoprotein cholesterol lowering.4–6 Therefore, low-density lipoprotein cholesterol reduction deals with only a portion of cardiovascular risk in CKD, and additional causes of accelerated atherosclerosis must be explored to devise new treatments.

Clinical Perspective on p 996

Multiple risk factors for coronary heart disease have been identified in CKD,5 beginning with mild impairments in renal function above an estimated glomerular filtration rate of 60 mL·min⁻¹·1.73 m⁻²; however, the significance and interrelationships among these risk factors are not well understood.

Received September 17, 2012; accepted January 22, 2013.
From the Division of Nephrology (A.G.) and Division of Molecular Medicine (A.G., L.Y.-C., D.A., A.R.T.), College of Physicians & Surgeons, Columbia University, New York, NY; Department of Cardiology (M.M.) and Center of Emergency Medicine (B.H., O.M.), Skåne University Hospital, Malmö, Sweden; Department of Clinical Sciences , Lund University, Malmö, Sweden (M.M., B.H., G.E., O.M.); Cardiology Division and Cardiovascular Research Center (T.J.W., R.E.G.) and Center for Immunology and Inflammatory Diseases (R.E.G.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Broad Institute of MIT and Harvard University, Cambridge, MA (R.E.G.).
*Dr's Ganda and Magnusson contributed equally to this work.
†Dr's Melander and Tall contributed equally to this work.
‡The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.112.000682/-/DC1.

Correspondence to Anjali Ganda, MD, MS, Division of Nephrology, College of Physicians & Surgeons, Columbia University, PH4–124, 622 W 168th St, New York, New York 10032. E-mail a.ganda@columbia.edu

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.112.000682
Patients with mild renal dysfunction develop an unfavorable lipid profile characterized by rising triglyceride and declining high-density lipoprotein cholesterol (HDL-C) concentrations,3,7 each of which is independently associated with coronary heart disease.3 Atherogenic remnants of triglyceride-rich lipoproteins accumulate as plasma triglycerides rise,5 and patients with CKD3 and end stage renal disease (ESRD)3,7 are at increased risk for cardiovascular events6 and cardiovascular death9 from increasing atherosclerosis as shown by carotid intima-media thickness (IMT) measurements.9,10

The number of circulating monocytes and their differentiation into lipid-laden macrophages in the arterial wall are fundamental factors involved in plaque formation,11,12 and in recent years, peripheral monocyte count has emerged as a strong and independent predictor of cross-sectional and future atherosclerosis in large population-based cohorts.13,14 In patients with ESRD who are undergoing hemodialysis, total monocyte counts and certain monocyte subsets are increased cross-sectionally compared with healthy control subjects,15 and small studies have shown that specific subsets are associated with cardiovascular events and mortality in ESRD16 and CKD.17 In addition, spikes in monocyte count to >11% of total leukocytes over time are associated with a composite end point of ESRD and death.18 However, in predialysis stages of CKD, these small studies have not shown increased total monocyte counts at baseline compared with subjects without CKD,17,18 and to the best of our knowledge, a large-scale, detailed analysis of monocyte count as a marker of atherosclerosis in the setting of mild renal dysfunction has never been undertaken.

The ability of high-density lipoprotein (HDL) to stimulate removal of cholesterol from macrophages, cholesterol efflux, is thought to be central to its antiatherogenic mechanism.19 In mouse models, we recently discovered that the absence of ABCA1 and ABCG1, 2 ATP-binding cassette transporters that promote HDL-mediated cholesterol efflux,20 leads to proliferation of hematopoietic stem and progenitor cells, myeloid progenitor cells, and blood monocytes in association with accelerated atherosclerosis, and that transplantation of knockout bone marrow into apolipoprotein A1 (apoA1) transgenic mice with high HDL-C levels dramatically reverses this phenotype.20 We therefore hypothesized that individuals with mild renal dysfunction measured at the time of the screening examination in 759 MDC-CC individuals by use of previously described methodology21,22 (see the Methods section in the online-only Data Supplement for details). These subjects were derived from a nested incident cardiovascular disease case-control study (n=506)23 with case and control subjects matched by sex, age, and Framingham risk score24 and a nested incident diabetes case-control study (n=326).25 From this pool of 832, subjects were excluded who had cardiovascular disease before the baseline examination or incomplete data on cysC or who had been in both studies above, which left 759 individuals. There were 752 individuals with complete data on all covariates (metabolite cohort).

Clinical End Points

We primarily examined the surrogate cardiovascular end point, top quartile of monocytes, measured at the time of the screening examination and defined in the online-only Data Supplement, which notably has been associated with future coronary events in an adjusted analysis of >25 000 individuals from MDC.26 In MDC-CC, the top quartile of monocytes contained 0.70 to 1.80 million cells/mL, or a mean of 11% of total white blood cells. In addition, we examined a secondary end point at baseline: maximal carotid bulb IMT (IMT_Bulb), measured in millimeters (further details provided in the online-only Data Supplement).

Statistical Analysis

All analyses were performed cross-sectionally at the time of the baseline visit. We divided 4757 MDC-CC subjects with baseline cysC into cysC quintiles and initially hypothesized (1) that subjects in quintile 5 for cysC would have the lowest HDL-C level and the highest monocyte count and (2) that quintile 5 of cysC and HDL-C would each independently be associated with the categorical primary outcome of top quartile of monocytes after multivariable adjustment for age, sex, quintiles 1 to 4 cysC, HOMA-IR, and current smoking in a logistic regression model. Next, in 752 of these subjects, we explored the relationship of various candidate amino acid (AA) metabolites previously shown to have inverse associations with HDL-C23 to top quartile monocytes. Each metabolite was examined in a separate multivariable logistic regression model adjusted for age, sex, continuous (standardized) cysC, HDL-C, and HOMA-IR. All metabolite values were subjected to natural logarithm transformations because of their nonnormal distribution and then standardized (to mean=0, SD=1). Finally, using a multivariable linear regression model adjusted for age, sex, quintiles 1 to 4 cysC, HOMA-IR, and current smoking, we hypothesized that quintile 5 of cysC, HDL-C, and continuous monocytes would each independently be associated

Methods

Study Population

All human study protocols were approved by the Institutional Review Board of Lund University (Sweden). All study participants provided written informed consent. The Malmö Diet and Cancer Study (MDC) is a prospective, population-based cohort that included 28449 randomly selected men (born between 1923 and 1945) and women (born between 1923 and 1950) who underwent a baseline examination between 1991 and 1996. From this cohort, 6103 persons enrolled in 1991 to 1994 were randomly selected to participate in the MDC cardiovascular cohort (MDC-CC), which was designed to investigate the epidemiology of carotid artery disease. We excluded participants with prior myocardial infarction or stroke at baseline (n=143). Of the remaining participants, fasting plasma samples at baseline were available for 5400.25 Among these, complete data on conventional cardiovascular risk factors were available for 5220. To assess the cross-sectional clinical end points below, we divided 4757 MDC-CC individuals who had cysC measured at baseline into cysC quintiles.

Clinical Examination and Laboratory Assays

MDC participants underwent baseline history, examination, and laboratory assessment. Fasting EDTA plasma was frozen at –80°C immediately after collection. CysC, an endogenous substance freely filtered by the kidney, captures the association of mild renal dysfunction with cardiovascular risk better than creatinine-based glomerular filtration rate equations and is often preferred for use in assessment of cardiovascular end points in these individuals.21,22 CysC, fasting levels of HDL-C and triglyceride, the homeostasis model assessment of insulin resistance (HOMA-IR),26 and total and differential peripheral leukocytes were measured as described in the Methods section of the online-only Data Supplement.

Metabolite Profiling

Metabolites were profiled from EDTA plasma collected at the baseline examination in 759 MDC-CC individuals by use of previously described methodology21,22 (see the Methods section in the online-only Data Supplement for details). These subjects were derived from a nested incident cardiovascular disease case-control study (n=506)23 with case and control subjects matched by sex, age, and Framingham risk score24 and a nested incident diabetes case-control study (n=326).25 From this pool of 832, subjects were excluded who had cardiovascular disease before the baseline examination or incomplete data on cysC or who had been in both studies above, which left 759 individuals. There were 752 individuals with complete data on all covariates (metabolite cohort).

Clinical End Points

We primarily examined the surrogate cardiovascular end point, top quartile of monocytes, measured at the time of the screening examination and defined in the online-only Data Supplement, which notably has been associated with future coronary events in an adjusted analysis of >25 000 individuals from MDC.26 In MDC-CC, the top quartile of monocytes contained 0.70 to 1.80 million cells/mL, or a mean of 11% of total white blood cells. In addition, we examined a secondary end point at baseline: maximal carotid bulb IMT (IMT_Bulb), measured in millimeters (further details provided in the online-only Data Supplement).

Statistical Analysis

All analyses were performed cross-sectionally at the time of the baseline visit. We divided 4757 MDC-CC subjects with baseline cysC into cysC quintiles and initially hypothesized (1) that subjects in quintile 5 for cysC would have the lowest HDL-C level and the highest monocyte count and (2) that quintile 5 of cysC and HDL-C would each independently be associated with the categorical primary outcome of top quartile of monocytes after multivariable adjustment for age, sex, quintiles 1 to 4 cysC, HOMA-IR, and current smoking in a logistic regression model. Next, in 752 of these subjects, we explored the relationship of various candidate amino acid (AA) metabolites previously shown to have inverse associations with HDL-C23 to top quartile monocytes. Each metabolite was examined in a separate multivariable logistic regression model adjusted for age, sex, continuous (standardized) cysC, HDL-C, and HOMA-IR. All metabolite values were subjected to natural logarithm transformations because of their nonnormal distribution and then standardized (to mean=0, SD=1). Finally, using a multivariable linear regression model adjusted for age, sex, quintiles 1 to 4 cysC, HOMA-IR, and current smoking, we hypothesized that quintile 5 of cysC, HDL-C, and continuous monocytes would each independently be associated
with the continuous secondary outcome IMT_{carotid bulb} (log transformed because of its skewed distribution). In all analyses, HOMA-IR was also log transformed because of its skewed distribution.

All analyses were performed with SAS version 9.1.3 (SAS Institute, Cary, NC). Continuous variables are summarized as mean±SD. ANOVA was used to test for a difference in HDL-C, triglyceride, monocyte, HOMA-IR, and AA means (respectively) across cysC quintiles. Results of logistic regression analyses are reported as odds ratio (ORs) with 95% confidence interval (CI). Results of linear regression analyses are reported as standardized regression coefficients (β, SE). A 2-tailed probability value of p<0.05 was considered statistically significant.

Results

Baseline characteristics of the MDC-CC human study sample and the metabolite cohort are shown in Table 1. Mean (±SD) age of subjects with complete data on conventional cardiovascular risk factors (n=5220) was 58±6 years, and 60% were women. Comparable age, sex distribution, and level of traditional risk factors were seen in the metabolite cohort (n=752).

MDC-CC Renal Demographics by CysC Quintiles

We divided 4757 MDC-CC subjects with baseline plasma cysC into cysC quintiles (Table 2). Quintile 5, which represented the highest cysC levels, contained 992 individuals with a cysC range from 0.88 to 3.29 mg/L. Given the mean cysC of 0.99±0.18 mg/L in this quintile and the corresponding mean estimated glomerular filtration rate of 69±15 mL·min⁻¹·1.73 m² (Table 2), we designated quintile 5 of cysC as “mild renal dysfunction.” Only 38 subjects had cysC ≥1.23 mg/L, which approximates an estimated glomerular filtration rate <60 mL·min⁻¹·1.73 m², commonly accepted as CKD.2

Table 1. MDC-CC: Baseline Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Complete Data on Conventional Cardiovascular Risk Factors* (n=5220)</th>
<th>Metabolite Cohort (n=752)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>58±6</td>
<td>59±6</td>
</tr>
<tr>
<td>Men</td>
<td>2044 (40)</td>
<td>373 (50)</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>141±19</td>
<td>147±19</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>87±9</td>
<td>90±9</td>
</tr>
<tr>
<td>Antihypertensive treatment</td>
<td>866 (17)</td>
<td>186 (25)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3224 (64)</td>
<td>577 (77)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.7±3.9</td>
<td>27±4</td>
</tr>
<tr>
<td>LDL-C, mg/dL</td>
<td>162.4±38.7</td>
<td>166.3±38.7</td>
</tr>
<tr>
<td>HDL-C, mg/dL</td>
<td>54.1±15.5</td>
<td>50.3±11.6</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>415 (8)</td>
<td>55 (7)</td>
</tr>
<tr>
<td>HOMA-IR, mean±SD</td>
<td>1.9±2.7</td>
<td>2.4±3.1</td>
</tr>
<tr>
<td>Current smoking</td>
<td>1365 (26)</td>
<td>230 (31)</td>
</tr>
</tbody>
</table>

Values are n (%) or mean±SD.

BMI indicates body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; MDC-CC, cardiovascular cohort of the Malmö Diet and Cancer Study; and SBP, systolic blood pressure.

*Complete data on conventional cardiovascular risk factors at baseline were available in 5220 individuals.

†Baseline plasma metabolite profiling was performed in 752 individuals with complete covariate data.

Mild Renal Dysfunction Is Linked to Low HDL-C Level and High Monocyte Count

In cross-sectional analysis of 4581 to 4757 MDC-CC individuals with available covariate data, lower levels of renal function marked by higher cysC concentrations were associated with lower fasting plasma HDL-C levels and higher monocyte counts (Table 3; Figure, A and C; P<0.001 [ANOVA]). The percentage decrease in HDL-C and increase in monocytes with lower levels of renal function across cysC quintiles 1 to 5 were similar: 14% and 11%, respectively. Consistent with our primary hypothesis, individuals in quintile 5 of cysC with mild renal dysfunction had the lowest plasma HDL-C level (49.4±13.7 mg/dL) and the highest monocyte count (0.54±0.19 million cells/mL). Because HDL-C levels are typically inversely correlated with plasma triglyceride levels,7 we also explored the relationship of triglyceride levels to cysC and indeed observed that individuals in quintile 5 of cysC had the highest plasma triglyceride level (139.7±70.6 mg/dL; Table 3; Figure, B) and the greatest insulin resistance (HOMA-IR score; Table 3).

Mild Renal Dysfunction Is Linked to a High-Risk Metabolic Profile

In 759 MDC-CC individuals derived from the nested incident cardiovascular disease case-control study27 and nested incident diabetes case-control study24 described above, we used a liquid chromatography–mass spectrometry–based platform22,24 to investigate whether branched-chain and aromatic AAs previously associated with insulin resistance and diabetes risk23,24 would be associated with worsening renal function. Higher cysC concentrations were associated with higher levels of the 3 AA score (isoleucine+phenylalanine+tyrosine) and the 5 AA score (isoleucine+phenylalanine+tyrosine+valine+leucine), which predict onset of future diabetes23 (Table 3; P=0.017 and P=0.048, respectively [ANOVA]). Of note, in previously published linear regression analyses adjusted for age and sex, each individual AA listed above has a highly significant inverse relationship with plasma triglycerides, and various associations with other metabolic traits and insulin resistance phenotypes, which highlights the connection of the AAs we measured to metabolic risk.21 Individuals in quintile 5 of cysC with mild renal dysfunction exhibited a high-risk profile, with elevated branched-chain and aromatic AAs, low HDL-C, high triglycerides, high HOMA-IR score, and high monocytes (Table 3).

Mild Renal Dysfunction and Low HDL-C Level Are Associated With Increased Risk of Being in the Top Quartile of Monocytes

In MDC, the top quartile of monocytes, measured at the time of the baseline examination and defined above, was associated with future coronary events in an adjusted analysis of >25 000 individuals.29 Therefore, we cross-sectionally examined the top quartile of monocytes as a surrogate cardiovascular end point in a multivariable logistic regression model that contained age, sex, log-transformed HOMA-IR, HDL-C, and quintiles 1 to 5 of cysC (n=4574; Table 4). Compared with quintile 1 of cysC, quintile 5 of cysC (mild renal dysfunction) was independently
Elevated Levels of Metabolites Tied to Low HDL-C Are Associated With Increased Risk of Being in the Top Quartile of Monocytes

In 752 MDC-CC individuals, we used a liquid chromatography–mass spectrometry–based platform to assess whether certain AA metabolites tied to low plasma HDL-C were also independently associated with increased odds of being in the top quartile of monocytes (Table 5). Individual multivariable logistic regression models contained the log-transformed and standardized candidate metabolite of interest, as well as age, sex, log-transformed HOMA-IR, cysC, and HDL-C. Tyrosine, glutamate, carnitine, alanine, n-carbamoyl-β-alanine, allantoin, and dimethylglycine, each of which has a known inverse association with HDL-C, were independently associated with 22% to 34% increased odds of being in the top quartile of monocytes (P<0.05 for all). a-Glycerophosphocholine, which is positively associated with plasma triglycerides, was independently associated with 23% increased odds of being in the top quartile of monocytes (P=0.02). Interestingly, the 3 AA score (isoleucine+phenylalanine+tyrosine), the components of which are inversely associated with plasma HDL-C and positively associated with plasma triglycerides, predicts onset of future diabetes and cardiovascular events and increases as renal function declines (Table 3). Each 1-SD increase of the 3 AA score was independently associated with a 28% increased odds of being in the top quartile of monocytes (OR, 1.281; 95% CI, 1.039–1.581; P=0.02). Glutamine, which is correlated with high plasma HDL-C and negatively associates with insulin resistance phenotypes, was nearly significantly associated with 14% reduced odds of being in the top quartile of monocytes (OR, 0.858; 95% CI, 0.714–1.030; P=0.1; Table 5).

Mild Renal Dysfunction, Low HDL-C Level, and Monocytes Are Independently Associated With Carotid Atherosclerosis

We examined the cross-sectional atherosclerosis end point IMT_Bulb (n=3134), measured in millimeters and log-transformed. A multivariable linear regression model to evaluate this atherosclerosis outcome contained sex, age, and baseline HOMA-IR and HDL-C level as covariates. We then considered the association of additional potential risk factors with the log transformed IMT_Bulb (Supplemental Digital Content 1). The additional potential variables were categorized according to renal function (eGFR), body mass index, and AA and other metabolite levels (Supplemental Table 8).

Table 2. MDC-CC: Renal Demographics by Cystatin C Quintiles

<table>
<thead>
<tr>
<th>CysC Quintile</th>
<th>CysC Range, mg/L</th>
<th>CysC, Mean±SD, eGFR (MDRD), Mean±SD</th>
<th>No. of Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.28–0.67</td>
<td>0.62±0.05</td>
<td>80.54±15.75</td>
</tr>
<tr>
<td>2</td>
<td>0.68–0.73</td>
<td>0.71±0.02</td>
<td>77.98±14.02</td>
</tr>
<tr>
<td>3</td>
<td>0.74–0.79</td>
<td>0.77±0.02</td>
<td>74.93±14.49</td>
</tr>
<tr>
<td>4</td>
<td>0.80–0.87</td>
<td>0.83±0.02</td>
<td>72.96±13.68</td>
</tr>
<tr>
<td>5</td>
<td>0.88–3.29</td>
<td>0.99±0.18</td>
<td>68.84±14.57</td>
</tr>
</tbody>
</table>

CysC indicates cystatin C; eGFR, estimated glomerular filtration rate; MDC-CC, cardiovascular cohort of the Malmö Diet and Cancer Study; and MDRD, Modification of Diet in Renal Disease.

*Baseline plasma cysC data were available in 4757 individuals, who were divided into cysC quintiles. eGFR was calculated using the MDRD Study equation.

Associated with 57% increased odds of being in the top quartile of monocytes (OR, 1.570; 95% CI, 1.215–2.029; P<0.001). Quintiles 2 to 4 of cysC were not independently associated with the top quartile of monocytes. CysC remained associated with the top quartile of monocytes when entered into the multivariable model as a standardized continuous variable instead of being divided into quintiles; however, the odds were attenuated (OR, 1.155; 95% CI, 1.072–1.246; P=0.001), which confirmed that individuals at greatest risk for increased monocytes were in quintile 5 of cysC. HDL-C level was independently associated with 42% decreased odds (OR, 0.576; 95% CI, 0.444–0.746; P<0.001). Age and baseline HOMA-IR were not associated with 38% decreased odds (OR, 0.624; 95% CI, 0.528–0.737; P=0.001). Female sex was also independently associated with 23% increased odds of being in the top quartile of monocytes (OR, 1.281; 95% CI, 1.039–1.581; P=0.02). Glutamine, which is correlated with high plasma HDL-C and negatively associates with insulin resistance phenotypes, was nearly significantly associated with 14% reduced odds of being in the top quartile of monocytes (OR, 0.858; 95% CI, 0.714–1.030; P=0.1; Table 5).

Table 3. MDC-CC: Metabolic Risk and Monocyte Count by Cystatin C Quintiles

<table>
<thead>
<tr>
<th>CysC Quintile</th>
<th>Three AA Score* (Isoleucine+Phenylalanine+Tyrosine)</th>
<th>HOMA-IR†</th>
<th>HDL-C Level,† mg/dL</th>
<th>TG Level,† mg/dL</th>
<th>Monocytes,† Million Cells/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>−0.19±0.98</td>
<td>1.7±1.9</td>
<td>57.6±14.6</td>
<td>101.5±57.8</td>
<td>0.48±0.17</td>
</tr>
<tr>
<td>2</td>
<td>−0.07±0.97</td>
<td>1.7±1.9</td>
<td>54.7±14.4</td>
<td>115.5±64.6</td>
<td>0.50±0.17</td>
</tr>
<tr>
<td>3</td>
<td>−0.03±0.97</td>
<td>2.0±2.4</td>
<td>52.8±13.8</td>
<td>122.8±69.6</td>
<td>0.51±0.18</td>
</tr>
<tr>
<td>4</td>
<td>0.15±1.08</td>
<td>2.0±2.2</td>
<td>51.1±13.1</td>
<td>131.7±85.5</td>
<td>0.51±0.16</td>
</tr>
<tr>
<td>5</td>
<td>0.13±0.96</td>
<td>2.6±4.7</td>
<td>49.4±13.7</td>
<td>139.7±70.6</td>
<td>0.54±0.19</td>
</tr>
</tbody>
</table>

*Baseline plasma metabolite profiling was performed in 759 individuals with complete data on cysC. All AA metabolite variables are log-transformed and standardized continuous variables.

†From 4757 subjects with baseline plasma cysC, the HOMA-IR (n=4581), plasma HDL-C (n=4662), TG (n=4709), and monocytes (n=4757) were measured. Monocytes were derived by an automatic cell counter 3-part differential method that distinguished cells on the basis of their size (lymphocytes, monocytes plus rare basophils/eosinophils, and neutrophils).
log-transformed HOMA-IR, HDL-C, quintiles 1 to 5 of cysC, and monocyte count (Table 6). Age was independently and strongly associated with IMT maxBulb (β=0.24; P<0.001). In addition, monocytes were independently and significantly associated with increased IMT maxBulb (P=0.02), which confirmed the results of other large studies linking monocytes to carotid IMT and atherosclerotic plaque formation.13,14

Figure. Mild renal dysfunction is linked to a low level of high-density lipoprotein (HDL) cholesterol, a high triglyceride level, and high numbers of monocytes. In cross-sectional analysis of 4662 to 4757 individuals in the cardiovascular cohort of the Malmö Diet and Cancer Study who had available covariate data, lower levels of renal function marked by higher cystatin C concentrations were associated with lower fasting plasma HDL levels (A), higher fasting plasma triglyceride levels (B), and higher monocyte counts (C) (P<0.001 for each, ANOVA). Results are shown as the mean of each variable by cystatin C quintile, with error bars representing the 95% confidence interval (CI). Monocytes were derived by an automatic cell counter 3-part differential method that distinguished cells on the basis of their size (lymphocytes, monocytes plus rare basophils/eosinophils, and neutrophils).

Table 4. MDC-CC: Independent Associations With Top Quartile of Monocytes*

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quintile 5 CysC</td>
<td>1.570</td>
<td>1.215–2.029</td>
<td>0.001</td>
<td>1.443</td>
<td>1.115–1.868</td>
<td>0.005</td>
</tr>
<tr>
<td>Quintile 4 CysC</td>
<td>1.120</td>
<td>0.861–1.458</td>
<td>0.397</td>
<td>1.069</td>
<td>0.821–1.393</td>
<td>0.620</td>
</tr>
<tr>
<td>Quintile 3 CysC</td>
<td>1.242</td>
<td>0.962–1.604</td>
<td>0.097</td>
<td>1.214</td>
<td>0.939–1.569</td>
<td>0.140</td>
</tr>
<tr>
<td>Quintile 2 CysC</td>
<td>1.097</td>
<td>0.846–1.422</td>
<td>0.486</td>
<td>1.074</td>
<td>0.827–1.394</td>
<td>0.592</td>
</tr>
<tr>
<td>Quintile 1 CysC</td>
<td>1.000</td>
<td>Referent</td>
<td>…</td>
<td>1.000</td>
<td>Referent</td>
<td>…</td>
</tr>
<tr>
<td>HDL-C</td>
<td>0.576</td>
<td>0.444–0.746</td>
<td>&lt;0.001</td>
<td>0.599</td>
<td>0.462–0.776</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>0.624</td>
<td>0.528–0.737</td>
<td>&lt;0.001</td>
<td>0.618</td>
<td>0.523–0.731</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age</td>
<td>1.003</td>
<td>0.989–1.017</td>
<td>0.665</td>
<td>1.009</td>
<td>0.995–1.023</td>
<td>0.216</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>0.970</td>
<td>0.734–1.282</td>
<td>0.830</td>
<td>1.030</td>
<td>0.780–1.361</td>
<td>0.834</td>
</tr>
<tr>
<td>Current smoking</td>
<td>…</td>
<td>…</td>
<td>…</td>
<td>1.713</td>
<td>1.450–2.023</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; CysC, cystatin C; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance (log-transformed); MDC-CC, cardiovascular cohort of the Malmö Diet and Cancer Study; and OR, odds ratio.

*All variables above were analyzed together in a multivariable logistic regression model (n=4574) to evaluate the outcome of top quartile of monocytes.
quintile 1 of cysC, was also independently and significantly associated with increased IMT_{maxBulb} ($P<0.01$). Quintiles 2 to 4 of cysC were not independently associated with IMT_{maxBulb}. When cysC was entered into the multivariable model (which contained monocytes and the other variables above) as a standardized continuous variable instead of divided into quintiles, it remained strongly and independently associated with IMT_{maxBulb} ($P<0.01$). Finally, low HDL-C level was independently associated with an increase ($P=0.02$) and female sex with a decrease ($P<0.001$) in IMT_{maxBulb} (Table 6). On further adjustment of our linear regression model for current smoking, low HDL-C and mild renal dysfunction (quintile 5 of cysC) remained significantly and independently associated with IMT_{maxBulb}. The association of monocytes with atherosclerosis in this expanded model was overshadowed by the strong effect of smoking (Table 6); however, in a published analysis of >25,000 MDC individuals, the top quartile of monocytes measured at the time of the baseline examination was associated with future coronary events independent of smoking.29

**Discussion**

It is well established that individuals with early decrements in renal function, measured by cysC, are at increased risk for cardiovascular events and death31,32; however, the mechanism underlying the strong relationship of cysC to cardiovascular risk has remained a matter of considerable debate.32–35 Because of the lack of independent association between cysC levels and carotid IMT in recent population-based studies,32,33 it has been suggested that in contrast to patients with CKD9 and ESRD,10 accelerated atherosclerosis may not be the primary mechanism explaining the independent relationship between cysC level and cardiovascular risk in individuals with early kidney disease.32,33 However, other studies demonstrated that in individuals with an estimated glomerular filtration rate >60 mL·min^{-1}·1.73 m^{-2}, cysC is associated with early-stage coronary atherosclerotic plaque morphology on multidetector computed tomography,34 as well as with coronary atherosclerosis extent by angiography,35 after adjustment for traditional risk factors. Because of the well-known association between cysC and cardiovascular events31,32 and the fact that cysC concentrations perform better than creatinine-based equations in predicting glomerular filtration rate in individuals at higher levels of renal function,36 we hypothesized that mild renal dysfunction measured by cysC would be associated with elevated monocyte count at baseline, an important marker and likely mediator of atherosclerotic plaque formation13,14 that is increased in ESRD.15

We now report in a cohort of >4500 individuals that even mild levels of renal dysfunction are accompanied by higher levels of circulating monocytes, and compared with the first quintile cysC, the fifth quintile cysC in the present study was strongly and independently associated with 44% to 57% increased odds of monocytosis at baseline, after adjustment for traditional risk factors. Consistent with our findings, a recent publication associated cysC with peripheral monocyte count in a small population sample (490 subjects)37 but did not relate monocytes to HDL-C levels or carotid IMT measurements. The present study, which was nearly 10 times larger, showed elevated monocyte counts in subjects with mild renal dysfunction and also demonstrated that low HDL-C and AA metabolites tied to low HDL-C23 were independently associated with the monocytosis of mild renal dysfunction. Moreover, we have shown a strong relationship of monocyte count with IMT at the carotid bifurcation, an area of low shear stress prone to early plaque formation,38 which suggests a direct mechanism of accelerated atherogenesis in mild renal dysfunction. We propose that the largely uneluciated mechanisms underlying the relationship of cysC to cardiovascular risk32,33 involve increased circulating monocytes and low HDL-C level, which leads to accelerated atherosclerosis. Importantly, although ESRD patients undergoing hemodialysis have elevated total monocyte counts compared with control subjects,15 small studies to date have not shown an increase in total monocyte counts at baseline in individuals with predialysis stages of CKD.17,18 The present new findings raise the possibility that low HDL-C may be causally related to defective cholesterol efflux in hematopoietic stem and progenitor cells and myeloid cells of patients with mild renal dysfunction, promoting increased monocyte formation.

We made the novel discovery that individuals in the fifth quintile of cysC exhibited a high-risk metabolic profile with elevated branched-chain and aromatic AAs and that the combination of isoleucine+phenylalanine+tyrosine not only forecasts diabetes24 and cardiovascular events27 but is independently associated with a 28% increased odds of being in the top quartile of monocyte count at baseline. Multiple other AA metabolites tied to low plasma HDL-C level and various other insulin resistance phenotypes (tyrosine, glutamate, carnitine, alanine, n-carbamoyl-beta-alanine, allantoin, dimethylglycine)23 were also independently associated with

### Table 5. Independent Metabolite Associations With Top Quartile of Monocytes*

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Three AA score (isoleucine+phenylalanine+tyrosine)</td>
<td>1.281</td>
<td>1.039–1.581</td>
<td>0.021</td>
</tr>
<tr>
<td>Five AA score (isoleucine+phenylalanine+tyrosine+valine+leucine)</td>
<td>1.239</td>
<td>1.004–1.530</td>
<td>0.046</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>1.335</td>
<td>1.098–1.624</td>
<td>0.004</td>
</tr>
<tr>
<td>Glutamate</td>
<td>1.295</td>
<td>1.072–1.563</td>
<td>0.007</td>
</tr>
<tr>
<td>Glutamine</td>
<td>0.858</td>
<td>0.714–1.030</td>
<td>0.100</td>
</tr>
<tr>
<td>Carnitine</td>
<td>1.241</td>
<td>1.025–1.502</td>
<td>0.027</td>
</tr>
<tr>
<td>Alanine</td>
<td>1.245</td>
<td>1.024–1.513</td>
<td>0.028</td>
</tr>
<tr>
<td>n-carbamoyl-beta-alanine</td>
<td>1.228</td>
<td>1.014–1.486</td>
<td>0.035</td>
</tr>
<tr>
<td>Allantoin</td>
<td>1.250</td>
<td>1.033–1.514</td>
<td>0.022</td>
</tr>
<tr>
<td>Dimethylglycine</td>
<td>1.220</td>
<td>1.013–1.470</td>
<td>0.036</td>
</tr>
<tr>
<td>a-Glycerophosphocholine</td>
<td>1.232</td>
<td>1.030–1.473</td>
<td>0.023</td>
</tr>
</tbody>
</table>

AA indicates amino acid; CI, confidence interval; and OR, odds ratio.

*Each AA variable above was analyzed in a separate multivariable logistic regression model that evaluated the outcome of top quartile of monocytes, adjusted for sex, age, log-transformed homeostasis model assessment of insulin resistance, high-density lipoprotein cholesterol, and continuous standardized cystatin C ($n=752$). All metabolite variables are log-transformed and standardized continuous variables. Ten other individual metabolites were analyzed that did not reach statistical significance: proline, adenosine, choline, seroton, taurine, trimethylamine N-oxide, phenylalanine, isoleucine, leucine, and valine.
increased odds of being in the top quartile of monocytes. Insulin resistance emerges with incipient renal disease, and the combination of CKD plus the metabolic syndrome is associated with cardiovascular events. The present findings suggest that new sensitive markers of insulin resistance and the metabolic syndrome may represent key underlying factors that contribute to increased monocytes in mild renal dysfunction.

One possible explanation for the relationship between AA metabolites and monocytosis relates to the mechanism by which nutritional factors contribute to insulin resistance. Exposure of cells to high physiological concentrations of branched-chain AAs activates mammalian target of rapamycin (mTORC1) signaling pathways important for protein synthesis and inhibits early steps in insulin action, which leads to decreased glucose use in skeletal muscle. mTORC1 is an evolutionarily conserved protein kinase that enhances cell growth and proliferation and suppresses autophagy, a degradative process in which intracellular contents are broken down in lysosomes to provide nutrients during periods of starvation.

Interestingly, it was very recently discovered that autophagy is required for cholesterol efflux to HDL and apolipoprotein A1 from murine macrophage foam cells, which suggests that major pathways that suppress autophagy, such as mTORC1, may be involved in defective cholesterol efflux and its downstream effects, including monocytosis. We therefore propose that AA-mediated activation of mTORC1 may be involved in impaired HDL-mediated cholesterol efflux via suppression of autophagy, and consistent with this hypothesis, we discovered that AA metabolites tied to low HDL-C were independently associated with increased odds of monocytosis.

Several limitations of the present study warrant consideration. First, the automatic cell counter that we used did not differentiate among monocytes and basophils/eosinophils; however, as published previously, the latter 2 leukocyte classes are rare compared with monocytes, and the same outcome that we examined was associated with future coronary events in a large adjusted analysis. This finding, as well as the significant and independent association we found between this count and carotid IMT, agrees with literature linking monocytes to carotid atherosclerosis and cardiovascular events and strengthens our results. HDL-C has been associated with monocyte count in studies one third to one fifth the size of the present study, both in healthy individuals and in subjects with the metabolic syndrome. The present much larger study extends this primary observation to a new population, demonstrating that HDL-C plays an important role in the monocytosis of individuals with mild renal dysfunction measured by cysC. We additionally showed that AA metabolites tied to low HDL-C and insulin resistance were associated with monocytosis and demonstrated a strong relationship of monocyte count with carotid IMT, which substantially implicates the present findings in atherogenesis. The failure of HDL-elevating therapies in recent clinical trials, as well as lack of a strong, direct relationship between HDL-elevating single-nucleotide polymorphisms and cardiovascular disease in human genome-wide association studies, has led to the suggestion that low HDL-C represents a risk marker only, possibly integrating the effects of insulin resistance, hypertriglyceridemia, remnant accumulation, and other factors, without a direct causal relationship to atherogenesis.

Whether low HDL-C levels contribute directly to monocytosis and atherosclerosis risk or represent a biomarker of metabolic risk cannot be discerned from our studies. In conclusion, we provide important evidence that cysC is significantly and independently associated with monocytosis and that the fifth quintile of cysC and monocytes were each independently associated with carotid IMT, which strongly suggests that accelerated atherosclerosis is responsible at least in part for increased cardiovascular disease risk in mild renal dysfunction. Increased monocyte counts at baseline in individuals with mild renal dysfunction may arise from low HDL-C levels, possibly reflecting defective cholesterol efflux pathways, and monocytosis and HDL-C levels are related to a high-risk AA signature that forecasts diabetes and cardiovascular events. Elevated monocytes may provide a previously unrecognized and key mechanism for the strong link between cysC and cardiovascular risk.

Table 6. MDC-CC: Independent Associations With Carotid Bulb Intima-Media Thickness*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Standardized β-Coefficient (SE)</th>
<th>P</th>
<th>Standardized β-Coefficient (SE)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.243 (0.001)</td>
<td>&lt;0.001</td>
<td>0.260 (0.001)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>−0.082 (0.006)</td>
<td>&lt;0.001</td>
<td>−0.085 (0.006)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Monocytes</td>
<td>0.039 (0.016)</td>
<td>0.024</td>
<td>0.024 (0.016)</td>
<td>0.173</td>
</tr>
<tr>
<td>HDL-C</td>
<td>−0.047 (0.009)</td>
<td>0.019</td>
<td>−0.040 (0.009)</td>
<td>0.044</td>
</tr>
<tr>
<td>Quintile 5 CysC</td>
<td>0.072 (0.009)</td>
<td>0.002</td>
<td>0.055 (0.009)</td>
<td>0.018</td>
</tr>
<tr>
<td>Quintile 4 CysC</td>
<td>0.017 (0.009)</td>
<td>0.455</td>
<td>0.007 (0.009)</td>
<td>0.761</td>
</tr>
<tr>
<td>Quintile 3 CysC</td>
<td>−0.002 (0.009)</td>
<td>0.915</td>
<td>−0.008 (0.009)</td>
<td>0.722</td>
</tr>
<tr>
<td>Quintile 2 CysC</td>
<td>0.008 (0.009)</td>
<td>0.725</td>
<td>0.003 (0.009)</td>
<td>0.894</td>
</tr>
<tr>
<td>Quintile 1 CysC</td>
<td>Referent</td>
<td>...</td>
<td>Referent</td>
<td>...</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>0.002 (0.011)</td>
<td>0.895</td>
<td>0.012 (0.010)</td>
<td>0.508</td>
</tr>
<tr>
<td>Current smoking</td>
<td>0.122 (0.006)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CysC indicates cystatin C; HDL-C, high-density lipoprotein cholesterol; and HOMA-IR, the homeostasis model assessment of insulin resistance (log-transformed).

*All variables above were analyzed together in a multivariable linear regression model (n=3134 for the outcome log-transformed maximal carotid bulb intima-media thickness).
Sources of Funding
Dr Ganda was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR000040, formerly the National Center for Research Resources, grant number UL1 RR024156. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was additionally supported by the Leducq Foundation. Drs Magnusson and Melander were supported by grants from the Swedish Medical Research Council, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University, Skåne University Hospital, the Albert Påhlsson Research Foundation, the Emholl Lundströms Research Foundation, the Region Skåne, the Hulda and Conrad Mossfelt Foundation, the Southwest Skanes Diabetes Foundation, the King Gustaf V and Queen Victoria Foundation, the Lennart Hanssons Memorial Fund, Knut and Alice Wallenberg Foundation, and the Marianne and Marcus Wallenberg Foundation. Dr Gerszten was supported by National Institutes of Health RO1 grants HL 98280 and DK 081572.

Disclosures
Drs Gerszten and Wang are named as coinventors on a patent application to the US Patent Office pertaining to metabolite predictors of diabetes mellitus. The remaining authors report no conflicts.

References
formation and accelerated atherosclerosis. To defective cholesterol efflux in hematopoietic stem and progenitor cells and myeloid cells, promoting increased monocyte proliferation of hematopoietic stem and progenitor cells, myeloid progenitor cells, and blood monocytes in animal models. In individuals with mild renal dysfunction, low high-density lipoprotein cholesterol may be causally related to monocytosis of mild renal dysfunction, and we show a strong relationship of monocyte count with carotid intima-media thickness in a healthy Chinese population. Hemodialysis and accelerated atherosclerosis. Atherosclerosis. 2003;169:331–337.


Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis
Anjali Ganda, Martin Magnusson, Laurent Yvan-Charvet, Bo Hedblad, Gunnar Engström, Ding Ai, Thomas J. Wang, Robert E. Gerszten, Olle Melander and Alan R. Tall

_Circulation_. 2013;127:988-996; originally published online February 1, 2013;
doi: 10.1161/CIRCULATIONAHA.112.000682

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/127/9/988

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2013/02/01/CIRCULATIONAHA.112.000682.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

Supplementary Methods

Clinical Examination and Laboratory Assays.
MDC participants underwent baseline history, examination, and laboratory assessment. Hypertension was defined as systolic blood pressure \( \geq 140 \text{ mmHg} \) or diastolic blood pressure \( \geq 90 \text{ mmHg} \), or use of antihypertensive therapy. Glucose was measured in venous whole blood. Diabetes was defined as fasting blood glucose \( \geq 6.1 \text{ mmol/L} \) (corresponding to fasting plasma glucose of \( \geq 7.0 \text{ mmol/L} \) or \( 126 \text{ mg/dL} \)), a self-reported physician diagnosis of diabetes, or use of anti-diabetic medication. Cigarette smoking was elicited by a self-administered questionnaire, with current cigarette smoking defined as any use within the past year.

Fasting EDTA plasma was frozen at \(-80^\circ\text{C}\) immediately after collection. CysC was analyzed using a particle-enhanced immunonephelometric assay (N Latex Cystatin C; Dade Behring, Deerfield, Illinois).\(^1\) Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Study equation.\(^3\) Fasting levels of HDL-C and TG were available in 4662 and 4709 of the 4757 individuals with baseline cysC and were measured according to standard procedures at the University Hospital Malmö. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as \([\text{fasting insulin (}\mu\text{U/ml}) \times \text{fasting glucose (mmol/l)}] / 22.5\) as previously described\(^4\) and was available in 4581 individuals.

Total and differential peripheral leukocytes were counted using a SYSMEX K1000 automatic cell counter (Sysmex Europe, Norderstedt, Germany). The analyses were performed at the
time of the screening examination, at the University Hospital Malmö, using fresh heparinized blood. The leukocyte histogram was discriminated into small, middle, and large sized leukocytes by a three-part differential method, providing the following information in 1 uL of whole blood: absolute count of lymphocytes (small cells), absolute count of monocytes plus basophils/eosinophils (middle sized cells), and absolute count of neutrophils (large cells).\textsuperscript{5} The baseline count of middle sized cells consists mainly of monocytes,\textsuperscript{5} and in line with smaller studies linking monocytes to atherosclerosis\textsuperscript{6-7} and CV events,\textsuperscript{8} it has recently been shown to predict future coronary events in a large adjusted analysis of over 25,000 individuals.\textsuperscript{5} We shall refer to this count as monocytes, given the relative scarcity of basophils/eosinophils compared to monocytes in this count.\textsuperscript{5} Monocytes were available in all 4757 MDC-CC individuals with baseline cysC.

**Metabolite Profiling.** Plasma samples were stored at -80˚ C and profiled using liquid chromatography-tandem mass spectrometry (LC-MS) as described previously.\textsuperscript{9-10} LC-MS was performed using a 4000 QTRAP triple quadrupole mass spectrometer (AB SCIEX, Foster City, CA), coupled to a multiplexed LC system including two 1200 Series pumps (Agilent Technologies, Santa Clara, CA) and an HTS PAL autosampler (Leap Technologies, Carrboro, NC) with 2 injection ports and a column selection valve. The two pumps were similarly configured for hydrophobic interaction chromatography (HILIC) using 150 x 2.1 mm Atlantis HILIC columns (Waters; Milford, MA). MultiQuant software v1.1 (AB SCIEX, Foster City, CA) was used for automated peak integration and metabolite peaks also were manually reviewed for quality of integration. Formic acid, ammonium acetate, LC-MS grade solvents, and valine-d8 were obtained from Sigma-Aldrich (St. Louis, MO), with the remainder of isotopically-labeled analytical standards obtained from Cambridge Isotope Laboratories, Inc. (Andover, MA). Internal standard peak areas were monitored for quality control and individual samples with
peak areas differing from the group mean by more than 2 standard deviations were re-analyzed. A complete list of metabolites analyzed is given in the sub-text of Table 5. Metabolites were selected based on the following criteria: 1) known structural identity; 2) distribution across multiple biochemical pathways; 3) reliable measurement using LC-MS in a high throughput fashion; and, 4) low rate of missingness on our platform (<1%). Using sample preparation and MS replicates of human samples, we have previously documented coefficients of variation (CV) for the metabolites in the platform: 54% of metabolites have CV ≤ 10% and 74% have CV ≤ 20%.9

Clinical Endpoints

We primarily examined the top quartile of monocytes, measured at the time of the screening exam and defined above. We examined a secondary endpoint at baseline: maximal carotid bulb IMT (IMT\textsubscript{maxBulb}). Using B-mode ultrasound, the right carotid bifurcation was scanned within a pre-defined “window” comprising 3 cm of the distal common carotid artery, the bifurcation, and 1 cm of the internal and external carotid artery, respectively. The maximum thickness of the intima–media (max IMT bifurcation) in the far wall of the carotid bifurcation was measured off-line according to the leading edge principle, using a specially designed computer-assisted image analyzing system as previously described.11 IMT\textsubscript{maxBulb} (measured in millimeters) was available in 3134 MDC-CC participants with available covariate data.

References for Supplementary Methods


6. Chapman CM, Beilby JP, McQuillan BM, Thompson PL, Hung J. Monocyte count, but not c-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. *Stroke.* 2004;35:1619-1624


